EYPT EyePoint Pharma: Enterprise Value to EBITDA Ratio

Retinal therapy implants are rapidly capturing the market by reducing the number of injections, although global raw material logistics and trade barriers create certain risks. The dynamic EV/EBITDA ratio of EyePoint Pharmaceuticals (EYPT) confirms the current market value, where this metric equals 0.00. This proves the effectiveness of the unique drug delivery systems that ensure EyePoint Pharmaceuticals (EYPT) maintains leadership in ophthalmology.

EyePoint Pharma - EYPT Company Value to EBITDA (period 11/23/2025 - 11/10/2026)

EYPT (eyepointpharma.com): analytical breakdowns and indicator data

- current price and projected stock value:

Stock Price EyePoint Pharma|EYPT - Average Forecast Price

- company stock capitalization data:

Market Valuation EyePoint Corp|EYPT - Total Enterprise Value

- business book valuation details:

Book Value per Share EyePoint Pharmaceuticals|EYPT - Total Stockholders' Equity|Market Value to Book Value Ratio eyepointpharma.com|EYPT - Company Total Asset Base

- debt and liquidity data:

- financial results and valuation multiples details:

EYPT - Company Net Income|Projected Future Earnings EyePoint Pharmaceuticals|EYPT - Business Payback Period|Future Price to Earnings EyePoint Pharmaceuticals|EYPT - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio EyePoint Corp|EYPT - Company profit before taxes, interest and amortization|Net earnings per share for the last 12 months EyePoint Pharmaceuticals|EYPT - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months eyepointpharma.com|EYPT - Earnings per share trend in current year|Earnings growth forecast for next year EyePoint Pharmaceuticals

Initial company analysis:EyePoint Pharma EYPT

Product sample of EyePoint Pharmaceuticals Inc

By analyzing the EV/EBITDA history of EyePoint Pharmaceuticals (EYPT), an investor assesses the enterprise value of the business relative to its ability to generate operating cash flow before depreciation and interest. This multiple allows for an objective comparison of the total asset value against the unique pricing power of this biotech leader, whose proprietary drug delivery systems determine the fundamental attractiveness and investment potential of the company.

Competitor analysis

EV/EBITDA Multiple ALC (Alcon Vision)|Bausch Health (BLCO) - Company Value to EBITDA|GKOS: Enterprise Value to EBITDA Ratio|Company Value to EBITDA apellis.com|BLTE: EV/EBITDA Multiple|Company Value to EBITDA Ocular Therapeutix Inc (OCUL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harrow Health|Viridian Corp (VRDN) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple LENZ|OCS - Company Value to EBITDA|Kodiak Sciences - Enterprise Value to EBITDA Ratio|Aldeyra Therapeutics Inc. (ALDX) - Company Value to EBITDA|Kala Pharmaceuticals - EV/EBITDA Multiple|Company Value to EBITDA Opus Genetics Inc|okyopharma.com (OKYO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ADVM (Adverum Biotechnologies, Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Outlook Therapeutics, Inc.|Company Value to EBITDA Clearside Biomedical Inc CLSD|EV/EBITDA Multiple NBY|Total Company Value to Operating Income Before Depreciation Ratio kiorapharma.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alimera Sciences, Inc. ALIM|EYEN: Enterprise Value to Operating Income Before Depreciation|GHSI: Enterprise Value to EBITDA Ratio|Ocuphire Pharma Inc - Enterprise Value to Operating Income Before Depreciation Ratio|OPT (Opthea Ltd.) - Enterprise Value to EBITDA Ratio